Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dean F Bajorin

Showing results (81-90 of 169) with videos related to

Pageof 17
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 19, 2024
Paclitaxel, Ifosfamide, and Cisplatin as Initial Salvage Chemotherapy for Germ Cell Tumors: Long-Term Follow-Up and Outcomes for Favorable- and Unfavorable-Risk DiseaseJack P Gleeson, Andrea Knezevic, Maria Bromberg, et al.
The Journal of Urology|April 16, 2020
Trends in Management and Outcomes among Patients with Urothelial Carcinoma Undergoing Radical Cystectomy from 1995 to 2015: The Memorial Sloan Kettering ExperienceNima Almassi, Eugene K Cha, Emily A Vertosick, et al.
The Oncologist|April 8, 2015
The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experienceRichard M Bambury, David J Benjamin, Joshua L Chaim, et al.
Clinical Genitourinary Cancer|May 7, 2016
Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial CancerPeter H O'Donnell, Shaheen Alanee, Kelly L Stratton, et al.
European Urology|August 25, 2012
ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settingsCora N Sternberg, Joaquim Bellmunt, Guru Sonpavde, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2016
Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell TumorsDarren R Feldman, James Hu, Tanya B Dorff, et al.
Clinical Genitourinary Cancer|May 1, 2018
Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of ImmunotherapyGuru Sonpavde, Gregory Russell Pond, Jonathan E Rosenberg, et al.
The Oncologist|February 15, 2021
Four Cycles of Etoposide plus Cisplatin for Patients with Good-Risk Advanced Germ Cell TumorsSamuel A Funt, Deaglan J McHugh, Stephanie Tsai, et al.
BJU International|April 18, 2021
Pathological and oncological outcomes in patients with sarcomatoid differentiation undergoing cystectomyNima Almassi, Emily A Vertosick, Daniel D Sjoberg, et al.
The Journal of Urology|March 6, 2020
Utility of Routine Preoperative <sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography/Computerized Tomography in Identifying Pathological Lymph Node Metastases at Radical CystectomyShawn Dason, Nathan C Wong, Timothy F Donahue, et al.
Pageof 17

Showing results (81-90 of 169) with videos related to

Sort By:
Pageof 17
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 19, 2024
Paclitaxel, Ifosfamide, and Cisplatin as Initial Salvage Chemotherapy for Germ Cell Tumors: Long-Term Follow-Up and Outcomes for Favorable- and Unfavorable-Risk DiseaseJack P Gleeson, Andrea Knezevic, Maria Bromberg, et al.
The Journal of Urology|April 16, 2020
Trends in Management and Outcomes among Patients with Urothelial Carcinoma Undergoing Radical Cystectomy from 1995 to 2015: The Memorial Sloan Kettering ExperienceNima Almassi, Eugene K Cha, Emily A Vertosick, et al.
The Oncologist|April 8, 2015
The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experienceRichard M Bambury, David J Benjamin, Joshua L Chaim, et al.
Clinical Genitourinary Cancer|May 7, 2016
Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial CancerPeter H O'Donnell, Shaheen Alanee, Kelly L Stratton, et al.
European Urology|August 25, 2012
ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settingsCora N Sternberg, Joaquim Bellmunt, Guru Sonpavde, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2016
Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell TumorsDarren R Feldman, James Hu, Tanya B Dorff, et al.
Clinical Genitourinary Cancer|May 1, 2018
Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of ImmunotherapyGuru Sonpavde, Gregory Russell Pond, Jonathan E Rosenberg, et al.
The Oncologist|February 15, 2021
Four Cycles of Etoposide plus Cisplatin for Patients with Good-Risk Advanced Germ Cell TumorsSamuel A Funt, Deaglan J McHugh, Stephanie Tsai, et al.
BJU International|April 18, 2021
Pathological and oncological outcomes in patients with sarcomatoid differentiation undergoing cystectomyNima Almassi, Emily A Vertosick, Daniel D Sjoberg, et al.
The Journal of Urology|March 6, 2020
Utility of Routine Preoperative <sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography/Computerized Tomography in Identifying Pathological Lymph Node Metastases at Radical CystectomyShawn Dason, Nathan C Wong, Timothy F Donahue, et al.
Pageof 17